A Phase 4 interventional study of Sacubitril/valsartan and Enalapril in Chagas Disease and Heart Failure, sponsored by Novartis Pharmaceuticals. Completed at 79 sites in 4 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Chagas Disease with a site in Brazil — 2 open to participants now, 3 under way, 1 of them phase 3. Chagas Disease · Brazil.
Among the 28 studies in Chagas Disease with a site in Brazil, this one is the 3rd largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 4, and was the 23rd registered.
73 studies on the registry are indexed under Chagas Disease; 5 are open to participants now.
Browse Chagas Disease studies →2 of the 28 studies in Chagas Disease with a site in Brazil are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Brazil, United States, Argentina and 1 more country
Ages 18–60
University of Sao Paulo General Hospital · Sites in Brazil
Ages 18+
A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →
Of the 3 Chagas Disease studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 6 · Phase 4 4
First in 2004; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 922 is above the median of 87 across 49 interventional studies indexed under Chagas Disease.
Median enrollment 60 across the 21 interventional studies, 60 across the 7 observational. Of the 18 that completed or were terminated, 2 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Chagas Disease — fewer than ten, so there is no comparison to draw.
1 of the studies in Chagas Disease with a site in Brazil that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06632600Novartis PharmaceuticalsA Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. | 2027-07-22 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies in Chagas Disease with a site in Brazil, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the effect of sacubitril/valsartan 200 mg BID compared with enalapril 10 mg BID, in addition to conventional heart failure (HF) treatment, in improving a hierarchical composite of cardiovascular (CV) events (i.e. CV death or the occurrence of first HF hospitalization) and causing a greater reduction in n terminal prohormone of brain natriuretic peptide (NT-proBNP, at Week 12 from Baseline) in participants with HF with reduced ejection fraction (HFrEF) caused by chronic Chagas' cardiomyopathy (CCC).
This was a multinational, multicenter, parallel-group, prospective, randomized, open-label, with blinded-endpoint adjudication, active-controlled study. The target projected sample size was approximately 900 participants (450 in each arm). It was estimated that approximately 1800 participants would be screened at sites in Latin America, including Argentina, Brazil, Colombia, and Mexico.
Participants who met the eligibility requirements were randomly assigned in a 1:1 ratio to receive sacubitril/valsartan (target dose of 200 mg twice daily) or enalapril (target dose of 10 mg twice daily), in addition to their usual therapy, stratified by country, using a central, concealed, web-based, automated randomization system. Both groups entered a titration period of 3 to 6 weeks, aiming to achieve the target dose of sacubitril/valsartan 200 mg twice daily or enalapril 10 mg twice daily. The study follow-up succeeded the titration period and was to last until a total number of 302 events was reached and all randomized participants had a minimum follow-up of 12 weeks.
Key Inclusion Criteria:
Diagnosis of Class II-IV HFrEF established by:
Key Exclusion Criteria:
Patients requiring continuous intravenous inotropic therapy or with indication of advanced support intervention for HF:
Presence of other cardiac conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 to 6 weeks of titrated dosing with sacubitril/valsartan to achieve the target dose of 200 mg twice daily.
Drug: Sacubitril/valsartan
Participants received 3 to 6 weeks of titrated dosing with enalapril to achieve the target dose of 10 mg twice daily.
Drug: Enalapril
Drug pages: Sacubitril · Valsartan
Participants randomized to sacubitril/valsartan who were previously treated with angiotensin-converting enzyme inhibitors (ACEIs) had a 36-hour washout prior to receiving oral treatment with 50, 100, or 200 mg, film-coated tablets.
Also known as: LCZ696; Entresto; Vymada
Oral treatment with 5 or 10 mg tablets.
Also known as: Renitec
Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12
The primary efficacy endpoint was analyzed using the win ratio approach comparing every participant in the sacubitril/valsartan arm to every participant in the enalapril arm to determine a winner. A winner in the pair-wise comparison had a delayed time to the occurrence of CV death; if time to the occurrence of CV death was censored, a winner had a delayed time to the occurrence of first HF hospitalization event; if the times to both CV events were censored, a winner had a more favorable (less increase or more decrease) change in NT-proBNP between Baseline and Week 12. The estimated win ratio was defined as the total number of winners in the sacubitril/valsartan arm divided by the total number of winners in the enalapril arm. A win ratio \>1 represents a favorable outcome for the study drug being assessed.
Time frame: Total follow-up time up to approximately 36 months
Percentage of Participants Who Died From Cardiovascular Causes
Time frame: Total follow up time up to approximately 36 months
Percentage of Participants With First Hospitalization for Worsening Heart Failure
Time frame: Total follow up time up to approximately 36 months
Change From Baseline to Week 12 in NT-proBNP Levels
Geometric mean factor change was derived from a linear regression model of log(NT-proBNP), adjusted for country and baseline value.
Time frame: Baseline to Week 12
Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes
Time frame: From the date of randomization to the first occurrence (total follow up time up to approximately 36 months)
Percentage of Participants Who Died From Any Cause
Time frame: From date of randomization until the date of death from any cause assessed up to the end of the study, up to approximately 36 months
Number of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest
Time frame: From date of randomization until the date of the sudden death or resuscitated sudden cardiac arrest assessed up to the end of the study, up to approximately 36 months
Number of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required
Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Number of Days Alive and Out of the Hospital
The duration of hospital-free survival within 1 year from randomization was summarized.
Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Number of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events)
Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Number of Ventricular Fibrillation or Sustained Ventricular Tachycardia
The number of ventricular fibrillation or sustained ventricular tachycardia needing specific pharmacological, electrical or other treatment was determined.
Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
Number of Anti-tachycardia Pacing or Shock Therapies
Time frame: From the date of randomization up to end of study. Total follow up time up to approximately 36 months.
| Milestone | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Started | 462 | 460 |
| Completed | 333 | 318 |
| Not completed | 129 | 142 |
| Withdrew: Withdrawal of participant consent | 2 | 8 |
| Withdrew: Death | 127 | 134 |
The primary efficacy endpoint was analyzed using the win ratio approach comparing every participant in the sacubitril/valsartan arm to every participant in the enalapril arm to determine a winner. A winner in the pair-wise comparison had a delayed time to the occurrence of CV death; if time to the occurrence of CV death was censored, a winner had a delayed time to the occurrence of first HF hospitalization event; if the times to both CV events were censored, a winner had a more favorable (less increase or more decrease) change in NT-proBNP between Baseline and Week 12. The estimated win ratio was defined as the total number of winners in the sacubitril/valsartan arm divided by the total number of winners in the enalapril arm. A win ratio \>1 represents a favorable outcome for the study drug being assessed.
| wins | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Hierarchical Composite Endpoint Composed of Time to Cardiovascular (CV) Death, Time to First Heart Failure (HF) Hospitalization, and Relative Change in NT-proBNP From Baseline to Week 12 | 103086 | 67097 |
| percentage of participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Percentage of Participants With First Hospitalization Due to Heart Failure or Death From Cardiovascular Causes | 33.5 | 36.7 |
| percentage of participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Percentage of Participants Who Died From Any Cause | 27.9 | 29.1 |
| participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Participants Who Had Sudden Death or Resuscitated Sudden Cardiac Arrest | 46 | 39 |
| participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Participants Who Had Visits to an Emergency Room Due to Heart Failure (HF) Where Intravenous Therapy Was Required | 23 | 21 |
The duration of hospital-free survival within 1 year from randomization was summarized.
| days | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Days Alive and Out of the Hospital | 339 ± 72 | 338 ± 71 |
| hospitalizations | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Hospitalizations Due to Heart Failure (HF) or Death Due to Cardiovascular (CV) Causes (Recurrent Events) | 289 | 316 |
The number of ventricular fibrillation or sustained ventricular tachycardia needing specific pharmacological, electrical or other treatment was determined.
| events | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Ventricular Fibrillation or Sustained Ventricular Tachycardia | 42 | 32 |
| events | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Number of Anti-tachycardia Pacing or Shock Therapies | 17 | 13 |
On-treatment deaths: from first dose of study treatment to 30 days following the last dose of study treatment at the end of treatment phase. Survival follow-up deaths: from Day 31 after last dose of study treatment up to study completion.
| Participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| On-treatment deaths | 127 | 134 |
| Post-treatment survival follow-up deaths | 2 | 0 |
| All deaths | 129 | 134 |
| percentage of participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Percentage of Participants Who Died From Cardiovascular Causes | 23.8 | 25.4 |
| percentage of participants | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Percentage of Participants With First Hospitalization for Worsening Heart Failure | 22.1 | 24.1 |
Geometric mean factor change was derived from a linear regression model of log(NT-proBNP), adjusted for country and baseline value.
| picograms per milliliter | Sacubitril/Valsartan | Enalapril |
|---|---|---|
| Change From Baseline to Week 12 in NT-proBNP Levels | 0.62 (0.56 to 0.69) | 0.91 (0.82 to 1.01) |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 55 months. Deaths were also collected in the survival follow-up phase from 31 days after last dose of study medication until the end of the study, for an additional 8 months. These were not considered AEs.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sacubitril/@Valsartan | 129/462 (27.9%) | 169/462 (36.6%) | 102/462 (22.1%) |
| Enalapril | 134/460 (29.1%) | 183/460 (39.8%) | 145/460 (31.5%) |
| All Participants (Sacubitril/Valsartan and Enalapril) | 263/922 (28.5%) | 352/922 (38.2%) | 247/922 (26.8%) |
| Event | Sacubitril/@Valsartan | Enalapril | All Participants (Sacubitril/Valsartan and Enalapril) |
|---|---|---|---|
| Cardiac failureCardiac disorders | 14/462 | 23/460 | 37/922 |
| Acute kidney injuryRenal and urinary disorders | 15/462 | 16/460 | 31/922 |
| HypotensionVascular disorders | 11/462 | 15/460 | 26/922 |
| Ischaemic strokeNervous system disorders | 14/462 | 14/460 | 28/922 |
| Ventricular tachycardiaCardiac disorders | 14/462 | 11/460 | 25/922 |
| Ventricular arrhythmiaCardiac disorders | 12/462 | 13/460 | 25/922 |
| Pneumonia bacterialInfections and infestations | 8/462 | 12/460 | 20/922 |
| Septic shockInfections and infestations | 12/462 | 7/460 | 19/922 |
| Cardiac failure acuteCardiac disorders | 8/462 | 11/460 | 19/922 |
| PneumoniaInfections and infestations | 8/462 | 10/460 | 18/922 |
| Event | Sacubitril/@Valsartan | Enalapril | All Participants (Sacubitril/Valsartan and Enalapril) |
|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 14/462 | 54/460 | 68/922 |
| Cardiac failureCardiac disorders | 40/462 | 51/460 | 91/922 |
| HypotensionVascular disorders | 44/462 | 43/460 | 87/922 |
| Cardiac failure acuteCardiac disorders | 16/462 | 31/460 | 47/922 |
| Age, Continuous(years) | Sacubitril/Valsartan | Enalapril | Total |
|---|---|---|---|
| Mean | 64.1 ± 10.6 | 64.2 ± 11.0 | 64.2 ± 10.8 |
| Sex: Female, Male(Participants) | Sacubitril/Valsartan | Enalapril | Total |
|---|---|---|---|
| Female | 186 | 201 | 387 |
| Male | 276 | 259 | 535 |
| Race/Ethnicity, Customized(Participants) | Sacubitril/Valsartan | Enalapril | Total |
|---|---|---|---|
| Caucasian | 246 | 256 | 502 |
| Black | 70 | 70 | 140 |
| Indigenous | 24 | 18 | 42 |
| Mixed Ethnicity | 122 | 116 | 238 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Ran from Dec 2019 to primary completion in Mar 2025, 63 months.
Results were first posted in May 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sacubitril · Valsartan